AIM
AKBA icon

Alambic Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Alambic Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,134
Closed -$169K – 304
2018
Q3 		$169K Sell
19,134
-186,980
-91% -$1.67M 0.13% 225
2018
Q2 		$2.06M Buy
206,114
+65,514
+47% +$656K 0.56% 53
2018
Q1 		$1.34M Buy
+140,600
New +$1.97M 0.19% 192

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Alambic Investment Management's AKBA Position: Q4 2018 in Review

Alambic Investment Management sold out of Akebia Therapeutics (AKBA) in Q4 2018, closing a stake of 19,134 shares — an estimated $169K sold.

Alambic Investment Management first reported a position in AKBA in Q1 2018 and held it in 3 quarters. The position peaked at $2.06M in Q2 2018. 166 funds tracked by Wall St. Rank hold AKBA as of Q4 2018.

  • Alambic Investment Management reported no remaining Akebia Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Alambic Investment Management sold 19,134 Akebia Therapeutics shares in Q4 2018, an estimated $169K.
  • Alambic Investment Management first reported a position in Akebia Therapeutics in Q1 2018 and held it in 3 quarters.
  • Alambic Investment Management's Akebia Therapeutics position peaked at $2.06M in Q2 2018.
  • 166 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.